New Launch27 Oct 2025, 03:39 pm
Sai Life Sciences to Double Process R&D Capacity with New Facility in Hyderabad by September 2026
AI Summary
Sai Life Sciences, one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), has announced the groundbreaking of a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. The facility, expected to be operational by September 2026, will double the company’s Process R&D capacity and introduce new capabilities in peptide development, oligo intermediates & linkers, formulation development, and early-phase clinical supplies. The investment is part of the company’s planned capital expenditure, driven by increasing demand for late-stage development programs and scalable CMC capacity.
Key Highlights
- The new facility will double Sai Life Sciences’ Process R&D capacity.
- New capabilities will be introduced in peptide development, oligo intermediates & linkers, formulation development, and early-phase clinical supplies.
- The investment is part of the company’s planned capital expenditure.
- The new center is designed as a ‘Green Building’.
- The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization.